What does it cost to participate?
There is no cost to participate.
Where do the visits take place?
Visits take place at our General Clinic Research Center in Hewitt Hall on the UC Irvine campus in Irvine.
How long are the visits?
On average, a visit can last between 1-2 hours.
Do I need to stop taking my current medications to participate?
No, you can continue on your current medications. However, we do ask that your dosages have been stable for 3 to 4 months prior to screening.
Will I be given any feedback on the results of the study?
Yes. We can provide participants with copies of their clinical lab results, EKG tracings, and brain imaging reports when appropriate.
Will I be notified about the results of the study?
We cannot give you a copy of the publication, but we can direct you to the location where you may be able to obtain the information. We will be able to inform you of your study assignment (study drug vs. placebo) after the sponsor makes that information available.
Will there be compensation for my participation?
Some studies do provide compensation, but it varies from study to study.
Why should I participate in a clinical trial?
In some clinical trials, it is possible that the study drug may help your condition. Your participation in a clinical study may also increase the knowledge regarding the treatment of Alzheimer’s disease and help future patients.
Where can I find out more information about clinical trials?
You can contact our Clinical Trials Recruitment Coordinators at (949) 824-3250 or (949) 824-5733 or by email, Beatriz Yanez at firstname.lastname@example.org.
Is there a chance of getting a placebo during the trial?
In many studies, some of the participants are given placebo. This varies from study to study.
Are there any studies that are not double blind?
The majority of our studies are double-blind (i.e., a study in which both the investigator and the patient do not know whether the drug or placebo is being given). On some occasions we do conduct open label studies in which all participants receive the actual study medication. These studies, however, are usually restricted to those individuals that previously completed the double-blind study of the same medication.
Support Alzheimer’s research by joining us for upcoming events and educational opportunities.